NCT00025467View on ClinicalTrials.gov

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

July 31, 2007

Conditions
Endometrial AdenoacanthomaEndometrial AdenocarcinomaEndometrial Adenosquamous Cell CarcinomaEndometrial Clear Cell CarcinomaEndometrial Papillary Serous CarcinomaRecurrent Endometrial Carcinoma
Interventions
DRUG

thalidomide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00025467 - Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter